[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601121":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":26,"overallOfficials":32,"centralContacts":37,"locations":43,"responsibleParty":59,"collaborators":13,"id":61,"slug":13,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":13,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":13,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":13,"overallStatus":79,"whyStopped":13,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Adverse events","Incidence of adverse events","up to week 44",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":13,"interventionNames":24},"Stapokibatrt group","EXPERIMENTAL",[25],"Biological: Stapokibatrt",[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":13},"BIOLOGICAL","Stapokibatrt","Stapokibatrt Subcutaneous injection",[22],[33],{"name":34,"affiliation":35,"role":36},"Lin Ma","Beijing Children's Hospital","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":13,"email":42},"Qian Jia","CONTACT","028-88610620","qianjia@keymedbio.com",[44],{"facility":45,"status":13,"city":46,"state":47,"zip":13,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Beijing Children's Hospital Capital Medical University","Beijing","Beijing Municipality","China","CN",{"type":51,"coordinates":52},"Point",[53,54],116.39723,39.9075,{"lat":54,"lon":53},[57],{"name":34,"role":40,"phone":58,"phoneExt":13,"email":13},"+86 13601305676",{"type":60,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100601121",false,"NCT07106372","A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis","A Multi-center, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Stapokibatrt in Children With Atopic Dermatitis","Inclusion Criteria:\n\n* Voluntarily participate in the continuing study and sign the written Informed Consent Form(ICF).\n* Subjects who must complete the evaluation of Week 18 of the main study.\n* Have the ability to communicate well with the researcher and comply with the follow-up visits of the protocol.\n\nExclusion Criteria:\n\n* Planned major surgical procedure during the patient's participation in this study.\n* Any other circumstances in which the researcher deems not suitable to participate in this study.","ALL","2 Years","12 Years",{"count":71,"type":72},240,"ESTIMATED","INTERVENTIONAL",[75],"PHASE3","This is a multi-center, single-arm, open-label phase 3 study to evaluate the safety, efficacy, Pharmacokinetics(PK) and immunogenicity of Stapokibatrt in children with Atopic Dermatitis.",[78],"Atopic Dermatitis","NOT_YET_RECRUITING","2025-08-05",{"date":82,"type":83},"2025-08-06","ACTUAL",{"date":85,"type":72},"2025-09",{"date":87,"type":72},"2027-06",{"name":5,"class":6},1]